GlySens Incorporated President and CEO William H. Markle to Speak at Upcoming Healthcare Technology Conferences
SAN DIEGO, CA – November 5, 2018 – GlySens® Incorporated today announces it will participate in the 18th Annual Diabetes Technology Meeting as well as the 12th Annual Canaccord Genuity Medical Technologies & Diagnostics Forum. These speaking events will take place November 8th, in Bethesda, MD and November 15th, in New York, NY, respectively. The aim is to bring together esteemed healthcare faculty, regulatory officials along with capital investors and update GlySens’ latest innovations and growth opportunities. During these presentations William H. Markle, President & CEO of GlySens Incorporated, will explore how a novel Long-Term (1-year and next gen 2-year), Implantable Continuous Glucose Sensor can help individuals with diabetes and their care givers sustain the benefits of continuous glucose monitoring systems. The presentations will review current CGM system challenges and outline a long-term, unobtrusive, patient centric solution with benefits to all healthcare stakeholders (Patient, Clinician, Payor). The GlySens future of CGM is one that enables an ecosystem of interoperable diabetes devices that reduce burden and allow individuals to live more and worry less.
About GlySens Incorporated
GlySens Incorporated is a privately held corporation devoted to developing the world’s first unobtrusive, truly long-term continuous glucose monitoring system, intended to dramatically improve and simplify the lives of people with diabetes. The GlySens fully implanted sensor wirelessly communicates to an external display, designed to provide continuous, at-a-glance glucose reporting and alerts regarding hypo- and hyperglycemic glucose excursions. While other CGM approaches may require calibration multiple-times-per-day and demand continuous wearing of through-the-skin or skin-attached components, the calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from burdensome care and maintenance requirements. For people living with diabetes, the GlySens implantable continuous glucose monitoring system (the Eclipse® ICGM® System) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms. “Live more, worry less.”
Eclipse, ICGM and GlySens are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.
Caution – INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.